MAP3K1(MEKK1)
Sign in to save this workspaceUniProt Q13233 · PDB · AlphaFold · Substrate: MBP · Clone: aa 900-1748
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Lorlatinib | 68.2% | 31.8% | 97.24 | 0.694 |
| 2 | Pazopanib | 50.5% | 49.5% | 97.49 | 0.672 |
| 3 | Crizotinib | 45.8% | 54.2% | 91.39 | 0.581 |
| 4 | Bosutinib | 44.2% | 55.8% | 87.22 | 0.555 |
| 5 | Ponatinib | 42.3% | 57.7% | 78.23 | 0.534 |
| 6 | Ripretinib | 32.6% | 67.4% | 92.95 | 0.674 |
| 7 | Tivozanib | 29.3% | 70.7% | 92.42 | 0.673 |
| 8 | Dasatinib | 25.7% | 74.3% | 87.97 | 0.699 |
| 9 | Pexidartinib | 24.9% | 75.1% | 99.49 | 0.631 |
| 10 | Regorafenib | 19.6% | 80.4% | 95.99 | 0.719 |
| 11 | Sorafenib | 17.3% | 82.7% | 96.72 | 0.776 |
| 12 | Ibrutinib | 17.3% | 82.7% | 94.74 | 0.723 |
| 13 | Baricitinib | 17.1% | 82.9% | 97.99 | 0.616 |
| 14 | Ceritinib | 14.6% | 85.4% | 95.44 | 0.618 |
| 15 | Cabozantinib | 14.0% | 86.0% | 92.73 | 0.751 |
| 16 | Midostaurin | 13.0% | 87.0% | 78.64 | 0.500 |
| 17 | Ribociclib | 11.5% | 88.5% | 99.25 | 0.729 |
| 18 | Sunitinib | 11.3% | 88.7% | 91.73 | 0.524 |
| 19 | Dabrafenib | 11.0% | 89.0% | 94.74 | 0.633 |
| 20 | Erlotinib | 11.0% | 89.0% | 99.75 | 0.695 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.21
- Epithelial log2(TPM+1): 2.70
- Fold change: -0.49
- Status: No significant change
Selectivity landscape vs inhibition on MAP3K1
Each point is one of the 92 approved drugs; color = inhibition % on MAP3K1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…